Zhonghua Lin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Zhonghua Lin

Showing results (71-80 of 74) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 74 results.

Mabs|December 31, 2020

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor responseJosefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, et al.

Nature|May 17, 2023

Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.

JCI Insight|April 14, 2017

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.

Journal of Medicinal Chemistry|June 16, 2012

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.

Pageof 8

Search research articles

Showing results (71-80 of 74) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 74 results.

Mabs|December 31, 2020

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor responseJosefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, et al.

Nature|May 17, 2023

Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.

JCI Insight|April 14, 2017

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.

Journal of Medicinal Chemistry|June 16, 2012

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.

Pageof 8